Literature DB >> 10829060

Paclitaxel and cisplatin in ovarian cancer.

V Torri, P G Harper, N Colombo, J Sandercock, M K Parmar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10829060

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway.

Authors:  X Luo; Z Dong; Y Chen; L Yang; D Lai
Journal:  Cell Prolif       Date:  2013-08       Impact factor: 6.831

2.  Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.

Authors:  Ayesha B Alvero; Rui Chen; Han-Hsuan Fu; Michele Montagna; Peter E Schwartz; Thomas Rutherford; Dan-Arin Silasi; Karina D Steffensen; Marianne Waldstrom; Irene Visintin; Gil Mor
Journal:  Cell Cycle       Date:  2009-01-01       Impact factor: 4.534

Review 3.  Liposomal encapsulated anthracyclines: new therapeutic horizons.

Authors:  F M Muggia
Journal:  Curr Oncol Rep       Date:  2001-03       Impact factor: 5.945

Review 4.  First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.

Authors:  J Sandercock; M K B Parmar; V Torri; W Qian
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

5.  POU4F2/Brn-3b transcription factor is associated with survival and drug resistance in human ovarian cancer cells.

Authors:  Lauren J Maskell; Anupam V Mahadeo; Vishwanie S Budhram-Mahadeo
Journal:  Oncotarget       Date:  2018-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.